CAPTIVATE India - A Study to Assess the Prevalence of Cardiovascular Disease (CVD) in Individuals With Type 2 Diabetes Mellitus (T2DM) in India

Novo Nordisk A/S1,500 enrolled

Overview

This is a cross-sectional study assessing the prevalence of Cardiovascular Disease and describing cardio-renal risk factors among individuals with Type 2 Diabetes Mellitus in India based on medical records.

Study Type

OBSERVATIONAL

Enrollment

1,500

Conditions

Type 2 Diabetes Mellitus

Interventions

No treatment givenOTHER

No treatment given

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female individuals with type 2 diabetes mellitus (T2DM), aged above or equal to 18 years. * A confirmed diagnosis of T2DM before ethical clearance at every participating institution. * Medical records available between 01 January 2024 to 30 September 2024 ought to have the data points required for the primary and secondary objectives. Medical records must have at least 6 months (greater than or equal to 180 days) of follow-up data from the date of diagnosis. Exclusion Criteria: * Diagnosis of Type 1 diabetes, or maturity-onset diabetes of the young (MODY). * Known congenital heart disease or malformation.

Locations (1)

Novo Nordisk Investigational Site

Bangalore, Karnataka, India

Outcomes

Primary Outcomes

Proportion of individuals with established Cardio Vascular Disease (CVD)

Proportion

Time frame: From start of data collection to end of data collection (approximately 3 months)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.